MedTrace Logo

The Use of AKR1B10 for Monitoring Postoperative Recurrence of Hepatocellular Carcinoma

NCT06750159 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 400

Last updated 2024-12-27

No results posted yet for this study

Summary

Based on the clue that the serum marker AKR1B10 found in the investigators' previous study can be used as an effective indicator for detecting HCC and preHCC, the role and value of AKR1B10 as a new tumor marker for evaluating the recurrence monitoring of HCC after radical surgical resection needs further study, as to provide detailed clinical research data and scientific basis for improving the survival rate of HCC patients.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

OTHER

No intervention (observational study)

no intervention(observational study)

Sponsors & Collaborators

  • Peking Union Medical College Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-16
Primary Completion
2025-12-31
Completion
2029-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06750159 on ClinicalTrials.gov